Medichronal

Pharmacological properties

Medichronal darnitsa is a combination drug that helps to reduce the accumulation of toxic alcohol metabolites in the body, in particular acetic aldehyde (the product of ethanol oxidation).

The drug has a detoxifying effect, improves metabolic processes in the body, enhances the synthesis of catecholamines, especially norepinephrine, which improves neuromediation, stimulates the limbic-reticular complex, and increases the functional activity of the cerebral cortex.

The drug Medichronal-Darnitsa has a positive effect on liver function, and also improves sleep, overall well-being.

The reduction of symptoms of acute alcohol intoxication, symptoms of mild and moderate withdrawal symptoms occurs within 20-30 minutes after taking the drug.

Amino acetic acid is rapidly absorbed in the digestive tract. Has almost 100% bioavailability. It easily penetrates most body fluids and tissues. It is destroyed in the liver by the enzyme glycine oxidase.

Sodium formate is rapidly absorbed in the digestive tract. In the systemic circulation and body tissues, it reacts with acetaldehyde to form conjugates, which take part in the tricarboxylic acid cycle, and increases the formation of macroergic compounds.

Indications

Alcohol intoxication, withdrawal symptoms; to increase the effectiveness of other methods of therapy; prophylaxis of intoxication; secondary prevention of alcoholism.

Application

Medichronal-darnitsa is used in adults after meals, after dissolving the contents of both packets in ½ – ¾ cup (200 ml) of warm water. a single dose is 28.5 g (total weight of the components of both packages). to improve palatability, the contents of the bags can be dissolved in non-carbonated drinks (juice, compote, etc.).

To eliminate acute alcohol and withdrawal symptoms, the drug is used on the first day 1-2 times (after 10-12 hours) at a dose of 28.5 g, in the next 2-3 days - 28.5 g once a day.

In combination with other drugs in the treatment of chronic alcoholism and, if necessary, secondary prophylaxis, this drug is taken daily in one package (28.5 g) for 7 days in the form of 3 courses with a 3-day break between them. For the prevention of relapse 1–1.5 months after the course of treatment with Medichronal-Darnitsa, it is recommended to undergo a repeated 30-day course of therapy. It is also possible to use from 1 to 3 repeated short-term preventive treatment courses (7-14 days) throughout the year.

To prevent intoxication, it is necessary to take a single dose (the contents of packages No. 1 and No. 2) 30 minutes before drinking alcohol.

Contraindications

Hypersensitivity to the components of the drug; severe forms of diabetes mellitus, arterial hypotension.

Side effects

All components of the drug medichronal-darnitsa are natural metabolites, so it is well tolerated. In some cases, the following adverse reactions are possible:

from the nervous system: headache, tension, irritability, impaired concentration of attention;

from the gastrointestinal tract: nausea;

from the immune system: hypersensitivity reactions, including rash, itching, urticaria.

special instructions

Medichronal-darnitsa can be used both independently and in complex treatment. when prescribing treatment, it is necessary to use an individual approach, which may include changing the duration of treatment or increasing the number of repeated courses throughout the year.

In patients with a tendency to arterial hypotension, it is necessary to control the level of blood pressure and, if necessary, adjust the dose of the drug (prescribed in lower doses, subject to regular monitoring of blood pressure). With a decrease in blood pressure below the usual level, the drug is canceled.

Since the drug contains glucose, a condition for its use is a condition accompanied by hyperglycemia.

Use during pregnancy and lactation. Strictly controlled and adequate studies on the effectiveness and safety of the drug in pregnant women and breast-feeding women have not been conducted, therefore, use during pregnancy is possible if the benefit to the mother outweighs the potential risk to the fetus.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. During treatment, care should be taken when driving vehicles and working with complex mechanisms.

Children. Studies on the effectiveness and safety of the drug in children have not been conducted.

Interactions

The active substance of the drug - glycine - reduces the toxicity of anticonvulsants, antipsychotics, antidepressants, anticonvulsants.

With the combined use of the drug with tranquilizers, hypnotics and antipsychotics, the effect of CNS inhibition is enhanced.

Medichronal-Darnitsa can be used in combination with other drugs for the treatment of alcohol dependence, in addition to disulfiram. The use of disulfiram is possible after conducting courses of treatment with Medichronal-Darnitsa, if necessary.

Overdose

There is no information about the clinical manifestations of overdose. with an overdose, digestive disorders (nausea, bloating, diarrhea) and increased manifestations of adverse reactions are possible. symptomatic therapy.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° c.